Affiliation:
1. Molecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo s/n, Colonia Ejército de Oriente, Mexico City 09230, Mexico
2. Cátedra CONACYT, FES Zaragoza, National University of Mexico, Mexico City 09230, Mexico
Abstract
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway constitutes a rapid signaling module from the cell surface to the nucleus, and activates different cellular responses, such as proliferation, survival, migration, invasion, and inflammation. When the JAK/STAT pathway is altered, it contributes to cancer progression and metastasis. STAT proteins play a central role in developing cervical cancer, and inhibiting the JAK/STAT signaling may be necessary to induce tumor cell death. Several cancers show continuous activation of different STATs, including cervical cancer. The constitutive activation of STAT proteins is associated with a poor prognosis and overall survival. The human papillomavirus (HPV) oncoproteins E6 and E7 play an essential role in cervical cancer progression, and they activate the JAK/STAT pathway and other signals that induce proliferation, survival, and migration of cancer cells. Moreover, there is a crosstalk between the JAK/STAT signaling cascade with other signaling pathways, where a plethora of different proteins activate to induce gene transcription and cell responses that contribute to tumor growth. Therefore, inhibition of the JAK/STAT pathway shows promise as a new target in cancer treatment. In this review, we discuss the role of the JAK/STAT pathway components and the role of the HPV oncoproteins associated with cellular malignancy through the JAK/STAT proteins and other signaling pathways to induce tumor growth.
Funder
Dirección General de Asuntos del Personal Académico (DGAPA), Universidad Nacional Autónoma de México
Subject
Genetics (clinical),Genetics
Reference338 articles.
1. (2023, March 10). Available online: https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf.
2. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis;Arbyn;Lancet Glob. Health,2020
3. Duranti, S., Pietragalla, A., Daniele, G., Nero, C., Ciccarone, F., Scambia, G., and Lorusso, D. (2021). Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data. Cancers, 13.
4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
5. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study;Quint;Lancet Oncol.,2010
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献